FRANCIS LAURA sold $279K of SIBN

FRANCIS LAURA (Chief Executive Officer) sold 14,956 shares of SI-BONE, Inc. (SIBN) at an average of $18.66 ($18.63–$18.68, $0.28M total) across 5 trades on 2026-08-17.

Original reporting
SEC EDGAR · FRANCIS LAURA
Published Aug 18, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 9:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SIBN
Neutral
medium confidence
Mentioned
$SIBN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNNeutralLow
01

Why it matters

The disclosure provides incremental transparency on insider activity but does not introduce new operational or financial information about SI-BONE.

02

Market read

Traders may note insider selling as a minor sentiment input, but the article lacks any catalyst that would materially reprice the stock.

03

What to watch

The filing does not disclose reasons for the sale, and the post-transaction holdings remain large (493,900 shares), limiting interpretability.

Relevance 4/10Novelty 3/10Timing: Filed 2026-08-18 for trades dated 2026-08-17.

Background

This is an SEC Form 4 insider transaction by SI-BONE CEO Francis Laura, reporting open-market sales across five trades.

Company-level read

Ticker impact

$SIBNNeutralMedium confidence
Context

SI-BONE CEO Francis Laura sold about $279K of SIBN shares in an open-market transaction disclosed on Form 4.

Expected impact

Low near-term impact; any effect is likely sentiment-only and should fade unless paired with other news.

Evidence & confidence

The filing is a primary-source Form 4, but the disclosed sale size ($279K) is modest and does not include new company performance, guidance, or regulatory developments.

Market effects

No clear sector read-through from a single, modest insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or diversification needs; absence of a 10b5-1 plan does not necessarily imply negative expectations.

Key entities

  • SI-BONE, Inc.

    Company whose CEO insider sale is disclosed on Form 4.

  • Francis Laura

    Chief Executive Officer and director who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

$SIBNMed

SI-BONE (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.

$SIBNMed

SiBone Q3 Earnings Call Highlights

SiBone (SIBN) reported Q3 earnings, highlighting strong demand for its Onyx platform, which targets a $1.5B market. Gross profit rose 13.7% to $44.2M, with gross margin at 79.3%. Net loss narrowed to $3.6M. The company reaffirmed 2026 revenue guidance of $231M-$233M and expects Q4 momentum from physician growth and new products.